Baidu
map

J Hepatol:男男性接触的HIV患者中HCV的再感染率很高

2016-10-31 MedSci MedSci原创

在过去的十年中,男男性接触的HIV患者中,使用聚乙二醇干扰素和利巴韦林联合治疗急性丙型肝炎病毒感染的治愈率可达中等。然而,在已经清除病毒和对治疗有反应的男性中随后的HCV再感染发生率较高。采用回顾性分析探究来自奥地利、法国、德国和英国八个中心的男性HIV患者HCV的再感染率,时间为2002年5月至2014年6月。结果,606名自发清除HCV或治疗成功的患者中,149名(24.6%)患者出现了后续H

在过去的十年中,男男性接触的HIV患者中,使用聚乙二醇干扰素和利巴韦林联合治疗急性丙型肝炎病毒感染的治愈率可达中等。然而,在已经清除病毒和对治疗有反应的男性中随后的HCV再感染发生率较高。

采用回顾性分析探究来自奥地利、法国、德国和英国八个中心的男性HIV患者HCV的再感染率,时间为2002年5月至2014年6月。

结果,606名自发清除HCV或治疗成功的患者中,149名(24.6%)患者出现了后续HCV再感染。30名(共70名,43%)再次清除或治疗成功的患者发烧二次感染。再感染发生率为7.3/100人年(95% CI 6.2-8.6)。自发清除感染的患者较比接受治疗的患者再感染的发生率较低(危害比0.62,95% CI 0.38-1.02,P = 0.06)。再感染的自然清除与ALT的水平> 1000 IU/mL和先前感染的自然清除相关。

男男性接触的HIV患者中HCV感染是一个需要主要关心的问题。在此高风险群体种需要制定预防措施以减少发病率和治疗成本。存在HCV感染史的患者每3-6个月应检测其再感染情况,再感染者应每3个月检测一次。

原始出处:

Patrick Ingiliz, et al., HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2016.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2003355, encodeId=9343200335552, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Jan 14 10:50:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257651, encodeId=8ea1125e6514a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426681, encodeId=4e0314266811b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152661, encodeId=61581526619a, content=继续学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:59 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152660, encodeId=8abc152660cc, content=有意思~, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:51 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152512, encodeId=e756152512f7, content=好的很好的很好的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuKKTlMLXqAMJ8ynNGaqic2hekc7IZSW2QsmickyYrFgjJ0cw417M5uVjguMDCyEzA7UW1geVTDMuKu/0, createdBy=f80f1721714, createdName=漪佩飞飞, createdTime=Tue Nov 01 00:13:32 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2003355, encodeId=9343200335552, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Jan 14 10:50:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257651, encodeId=8ea1125e6514a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426681, encodeId=4e0314266811b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152661, encodeId=61581526619a, content=继续学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:59 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152660, encodeId=8abc152660cc, content=有意思~, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:51 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152512, encodeId=e756152512f7, content=好的很好的很好的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuKKTlMLXqAMJ8ynNGaqic2hekc7IZSW2QsmickyYrFgjJ0cw417M5uVjguMDCyEzA7UW1geVTDMuKu/0, createdBy=f80f1721714, createdName=漪佩飞飞, createdTime=Tue Nov 01 00:13:32 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-02 柳叶一刀
  3. [GetPortalCommentsPageByObjectIdResponse(id=2003355, encodeId=9343200335552, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Jan 14 10:50:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257651, encodeId=8ea1125e6514a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426681, encodeId=4e0314266811b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152661, encodeId=61581526619a, content=继续学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:59 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152660, encodeId=8abc152660cc, content=有意思~, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:51 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152512, encodeId=e756152512f7, content=好的很好的很好的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuKKTlMLXqAMJ8ynNGaqic2hekc7IZSW2QsmickyYrFgjJ0cw417M5uVjguMDCyEzA7UW1geVTDMuKu/0, createdBy=f80f1721714, createdName=漪佩飞飞, createdTime=Tue Nov 01 00:13:32 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-02 gwc384
  4. [GetPortalCommentsPageByObjectIdResponse(id=2003355, encodeId=9343200335552, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Jan 14 10:50:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257651, encodeId=8ea1125e6514a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426681, encodeId=4e0314266811b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152661, encodeId=61581526619a, content=继续学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:59 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152660, encodeId=8abc152660cc, content=有意思~, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:51 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152512, encodeId=e756152512f7, content=好的很好的很好的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuKKTlMLXqAMJ8ynNGaqic2hekc7IZSW2QsmickyYrFgjJ0cw417M5uVjguMDCyEzA7UW1geVTDMuKu/0, createdBy=f80f1721714, createdName=漪佩飞飞, createdTime=Tue Nov 01 00:13:32 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-01 保守主义

    继续学习~

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2003355, encodeId=9343200335552, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Jan 14 10:50:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257651, encodeId=8ea1125e6514a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426681, encodeId=4e0314266811b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152661, encodeId=61581526619a, content=继续学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:59 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152660, encodeId=8abc152660cc, content=有意思~, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:51 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152512, encodeId=e756152512f7, content=好的很好的很好的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuKKTlMLXqAMJ8ynNGaqic2hekc7IZSW2QsmickyYrFgjJ0cw417M5uVjguMDCyEzA7UW1geVTDMuKu/0, createdBy=f80f1721714, createdName=漪佩飞飞, createdTime=Tue Nov 01 00:13:32 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-01 保守主义

    有意思~

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2003355, encodeId=9343200335552, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Sat Jan 14 10:50:00 CST 2017, time=2017-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257651, encodeId=8ea1125e6514a, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426681, encodeId=4e0314266811b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 02 13:50:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152661, encodeId=61581526619a, content=继续学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:59 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152660, encodeId=8abc152660cc, content=有意思~, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Tue Nov 01 12:50:51 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152512, encodeId=e756152512f7, content=好的很好的很好的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuKKTlMLXqAMJ8ynNGaqic2hekc7IZSW2QsmickyYrFgjJ0cw417M5uVjguMDCyEzA7UW1geVTDMuKu/0, createdBy=f80f1721714, createdName=漪佩飞飞, createdTime=Tue Nov 01 00:13:32 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-01 漪佩飞飞

    好的很好的很好的!!!

    0

相关资讯

AIM:慢性肝病增加了HIV患者发生非霍奇金淋巴瘤的风险

在抗逆转录病毒疗法(ART)治疗的时代中,非霍奇金淋巴瘤(NHL)是最常见的艾滋病定义条件。慢性乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染是否会促进HIV感染患者患NHL目前还不清楚。来自意大利的研究人员开展了一项队列研究,该研究的目的是探讨慢性HBV和HCV感染是否与HIV感染患者的淋巴瘤发病率增高有关。该研究的数据来自于33个欧洲观察性HIV流行病学研究合作研究(COHERE)队列中的

Omega-3脂肪酸或可降低HIV患者心血管疾病的发病风险

据IDWeek 2016上一项新的研究展示表明,与安慰剂相比,接受抗逆转录病毒治疗稳定的HIV患者每日摄入较高水平的Omega-3脂肪酸可显著降低甘油三酯和C-反应蛋白的水平。HIV患者是心血管疾病的高危患者,该研究中,研究人员进行了一项随机对照试验以探究高剂量的ω-3脂肪酸在HIV患者中对血脂、炎症和血管功能的长期作用。研究共纳入了117名HIV感染者,均接受抗逆转录病毒治疗。随机分配分别每天接

ID Week:ω-3脂肪酸可降低HIV患者的甘油三酯

根据呈现在IDWeek 2016的研究数据,对于感染HIV、稳定ART的患者,每日高剂量ω-3脂肪酸,与安慰剂相比,可降低患者的甘油三酯和C-反应蛋白水平。塔夫斯大学医学中心的Gretchen Volpe博士说,心血管疾病在艾滋病病毒感染者中普遍存在。“艾滋病毒通过多种途径增加心血管疾病,包括血脂异常、慢性炎症和血管功能障碍,”她在这里的一个演讲中说。Volpe及其同事进行了她所说的最长的随机对照

吉利德HIV药物Truvada(特鲁瓦达)获英国NICE支持用于HIV暴露前预防治疗(PrEP)

美国生物技术巨头吉利德(Gilead)艾滋病管线近日在英国监管方面传来喜讯,英国国家卫生与临床优化研究所(NICE)已发布了一份有关HIV复方药Truvada用于感染高风险成人群体暴露前预防性治疗(PrEP)的证据总结。根据已获得的证据,Truvada在降低高危未感染成人群体中获得性HIV感染风险方面具有显著的临床疗效。此外,这份证据总结也表明,提供PrEP可能会增加其他健康服务的获取,例如艾

盘点:近期HIV研究进展汇总

治愈HIV经常被称作HIV研究的最终梦想。虽然有效的抗HIV药物已经将艾滋病转变成了一种慢性可控的疾病,你可以携带着HIV一直生活,并且不会死于HIV感染,但终生治疗与完全治愈仍然存在很大不同,如果能找到一种既经济又能够规模化开展的HIV治愈方法,现在寻找HIV治愈方法的研究得到了越来越多的关注。这里小M整理了近期脑卒中亮点研究进展及指南共识,与大家分享。【1】首例成功治癒的爱滋患者?英男体内

2016ACOG实践简报:HIV感染青少年和女性的妇科照护(No.167)发布

2016年10月,美国妇产科医师学会(ACOG)发布了HIV感染青少年和女性的妇科照护建议,以替代2010年12月发布的第117号指南和2013年9月发布的第572号委员会意见。本文的目的是对临床医生在HIV感染女性的基本健康检测和护理,家庭计划,妊娠护理以及常见妇科问题的管理等方面提供教育。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Baidu
map
Baidu
map
Baidu
map